Tapanainen J.S., Witchel S., Woolcock J., Yildiz B.O., Rombauts L., Mol B.W., Mansfield D., Joham A., Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., Piltonen T., Norman R.J., Andersen M., Azziz R., Balen A., Baye E., Boyle J., Brennan L., Broekmans F., Dabadghao P., Devoto L., Dewailly D., Downes L., Fauser B., Franks S., Garad R.M., Gibson-Helm M., Harrison C., Hart R., Hawkes R., Hirschberg A., Hoeger K., Hohmann F., Hohmann H., Vet D., Hutchison S., Johnson L., Jordan C., Kulkarni J., Legro R.S., Li R., Lujan M., Malhotra J., Marsh K., McAllister V., Mocanu E., Ng E., Oberfield S., Ottey S., Pena A., Qiao J., Redman L., Rodgers R., Romualdi D., Shah D., Speight J., Spritzer P.M., Stener-Victorin E., Stepto N., Tassone E.C., Thangaratinam S., Thondan M., Tzeng C.-R., van der Spuy Z., Vanky E., Vogiatzi M., Wan A., Wijeyaratne C., Tapanainen J.S., Witchel S., Woolcock J., Yildiz B.O., Rombauts L., Mol B.W., Mansfield D., Joham A., Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., Piltonen T., Norman R.J., Andersen M., Azziz R., Balen A., Baye E., Boyle J., Brennan L., Broekmans F., Dabadghao P., Devoto L., Dewailly D., Downes L., Fauser B., Franks S., Garad R.M., Gibson-Helm M., Harrison C., Hart R., Hawkes R., Hirschberg A., Hoeger K., Hohmann F., Hohmann H., Vet D., Hutchison S., Johnson L., Jordan C., Kulkarni J., Legro R.S., Li R., Lujan M., Malhotra J., Marsh K., McAllister V., Mocanu E., Ng E., Oberfield S., Ottey S., Pena A., Qiao J., Redman L., Rodgers R., Romualdi D., Shah D., Speight J., Spritzer P.M., Stener-Victorin E., Stepto N., Tassone E.C., Thangaratinam S., Thondan M., Tzeng C.-R., van der Spuy Z., Vanky E., Vogiatzi M., Wan A., and Wijeyaratne C.
Study Question: What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference?. Summary Answer: International evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS. What is Known Already: Previous guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist. Study Design, Size, Duration: International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength. Participants/Materials, Setting, Methods: Governance included a six continent international advisory and a project board, five guideline development groups (GDGs), and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation